INVO Fertility Inc IVF Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$0.56 down $0.03, 5.65% at close Oct 16
Last close · Previous close $0.59
- Market cap
- $995.89KAt the Oct 16 close
- P/E ratio
- PausedOn last 12 months’ EPS
See the note under the price. - Diluted EPS
- PausedLast 12 months
See the note under the price. - Dividend yield
- NoneLast 12 months
Price chart
$0.56down $0.38, 40.26%Past month
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$0.59Oct 15
- Volume79.88KOct 16 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume146.46KLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $0.51 to $30.00; now $0.56
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Oct 16 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
IVF trailed the S&P 500 in all 7 periods.
| Period | IVF and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | IVF: down 40.3% S&P 500: up 1.5% | IVF trailed the S&P 500 by 41.8 percentage points Trailed |
| 3M | IVF: down 50.7% S&P 500: up 1.9% | IVF trailed the S&P 500 by 52.6 percentage points Trailed |
| YTD | IVF: down 85.2% S&P 500: up 12.8% | IVF trailed the S&P 500 by 98.0 percentage points Trailed |
| 1Y | IVF: down 99.0% S&P 500: up 16.8% | IVF trailed the S&P 500 by 115.8 percentage points Trailed |
| Long term | ||
| 3Y | IVF: down 99.9% S&P 500: up 81.5% −91.6% vs +22.0% a year | IVF trailed the S&P 500 by 181.4 percentage points Trailed |
| 5Y | IVF: down 100.0% S&P 500: up 83.1% −91.3% vs +12.9% a year | IVF trailed the S&P 500 by 183.1 percentage points Trailed |
| 10Y | IVF: down 100.0% S&P 500: up 319.6% −74.0% vs +15.4% a year | IVF trailed the S&P 500 by 419.6 percentage points Trailed |
$10,000 invested in IVF 10 years ago (Oct 14, 2016) would be worth about $0 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $41,964.
IVF trailed the S&P 500 in all 7 periods.
| Period | IVF and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | IVF: down 40.3% S&P 500: up 1.2% | IVF trailed the S&P 500 by 41.5 percentage points Trailed |
| 3M | IVF: down 50.7% S&P 500: up 1.7% | IVF trailed the S&P 500 by 52.4 percentage points Trailed |
| YTD | IVF: down 85.2% S&P 500: up 11.9% | IVF trailed the S&P 500 by 97.1 percentage points Trailed |
| 1Y | IVF: down 99.0% S&P 500: up 15.5% | IVF trailed the S&P 500 by 114.5 percentage points Trailed |
| Long term | ||
| 3Y | IVF: down 99.9% S&P 500: up 75.0% −91.6% vs +20.5% a year | IVF trailed the S&P 500 by 174.9 percentage points Trailed |
| 5Y | IVF: down 100.0% S&P 500: up 71.2% −91.3% vs +11.4% a year | IVF trailed the S&P 500 by 171.2 percentage points Trailed |
| 10Y | IVF: down 100.0% S&P 500: up 258.1% −74.0% vs +13.6% a year | IVF trailed the S&P 500 by 358.1 percentage points Trailed |
$10,000 invested in IVF 10 years ago (Oct 14, 2016) would be worth about $0 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $35,813.
All-time high
$1,181,538.46
Closing high on . Now 100.0% below that record.
Split-adjusted daily closes since May 21, 2012.
Stock splits
7
Latest: 1-for-5 on . Share counts adjust after each split.
All 7 splits
- 1-for-5
- 1-for-8
- 1-for-3
- 1-for-12
- 1-for-20
- 5-for-8
- 1-for-20
Valuation
The Oct 16 close compared with the last 12 months of reported results (the four quarters to Jun 30, 2026). Tap a metric to see how it’s calculated. Per-share results and the measures based on them are paused. See the note under the price.
Price-to-earnings (P/E)
Paused
Other valuation measures
- 0.1×Last 12 months’ revenue
Market value divided by revenue over the last 12 months. Useful when earnings are small or negative.
P/S = Market cap ÷ Revenue (last 12 months)Price-to-sales ratio - Price-to-bookPausedBook value as of Jun 30, 2026
See the note under the price. - PEG ratioPausedLast 12 months’ EPS growth
See the note under the price. - −482.86%Last 12 months’ free cash flow
Free cash flow over the last 12 months as a share of the company’s market value: the cash the business generated for each dollar of stock.
FCF yield = Free cash flow (last 12 months) ÷ Market capFree cash flow - $777.08KAt the Oct 16 close
What it would cost to buy the whole business: the market cap at the Oct 16 close, plus debt, minus cash and short-term investments from the Jun 30, 2026 balance sheet.
EV = Market cap + Debt − Cash and short-term investmentsEV/EBITDA explained
Build your own IVF DCF in Excel. Value INVO Fertility with your own growth and margin assumptions.Browse DCF models Free DCF calculator
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q2 FY26, the quarter ended Jun 30, 2026. “Last 12 months” means the four quarters from Jul 1, 2025 to Jun 30, 2026, and balance-sheet figures are as of Jun 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $7.53Mup 13.8%
- Net income
- −$5.29M
- Diluted EPS
- PausedSee the note under the price.
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q3 FY24 (Sep 30, 2024) | $1.43M | −$1.63M | Paused See the note under the price. |
| Q4 FY24 (Dec 31, 2024) | $1.69M | −$3.79M | Paused See the note under the price. |
| Q1 FY25 (Mar 31, 2025) | $1.64M | −$17.40M | Paused See the note under the price. |
| Q2 FY25 (Jun 30, 2025) | $1.86M | −$3.62M | Paused See the note under the price. |
| Q3 FY25 (Sep 30, 2025) | $1.76M | −$2.64M | Paused See the note under the price. |
| Q4 FY25 (Dec 31, 2025) | $1.58M | $2.01M | Paused See the note under the price. |
| Q1 FY26 (Mar 31, 2026) | $2.02M | −$5.54M | Paused See the note under the price. |
| Q2 FY26 (Jun 30, 2026) | $2.18M | $888.74K | Paused See the note under the price. |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Dec 31, 2021) | $4.16M | −$6.65M | Paused See the note under the price. |
| FY22 (Dec 31, 2022) | $822.20K | −$10.89M | Paused See the note under the price. |
| FY23 (Dec 31, 2023) | $3.02M | −$8.03M | Paused See the note under the price. |
| FY24 (Dec 31, 2024) | $6.53M | −$9.26M | Paused See the note under the price. |
| FY25 (Dec 31, 2025) | $6.84M | −$23.32M | Paused See the note under the price. |
Margins
- Gross 35.3%
- Operating −78.7%
- Net −70.2%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- −$4.81MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow−$4.77MLast 12 months
- Capital spending$39.46KLast 12 months
- −63.9%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $3.61MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$0.00Last 12 months
Balance sheet
- $11.37MAs of Jun 30, 2026
Cash plus short- and long-term marketable securities on the Jun 30, 2026 balance sheet.
- Total debt$3.51MAs of Jun 30, 2026
- Net cash$7.85MAs of Jun 30, 2026
- Book value per sharePausedAs of Jun 30, 2026
See the note under the price. - 0.71As of Jun 30, 2026
Current assets divided by current liabilities on the Jun 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.21As of Jun 30, 2026
Total debt divided by shareholders’ equity on the Jun 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- 5 of 9Last 12 months
vs the 12 beforeA 0–9 checklist from accounting professor Joseph Piotroski. Each test compares the last 12 months with the 12 months before and scores a point if it passes. 8–9 is strong; 0–2 is weak.
- ✗Net income was positive: not passed
- ✗Operating cash flow was positive: not passed
- ✓Return on assets improved: passed
- ✓Operating cash flow exceeded net income: passed
- ✓Long-term debt fell relative to assets: passed
- ✓Current ratio improved: passed
- ✗Share count didn’t rise: not passed
- ✗Gross margin improved: not passed
- ✓Asset turnover (revenue ÷ assets) improved: passed
- −47.4%Last 12 months
Over the last 12 months, INVO Fertility lost money: its net loss was 47.4% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - −23.6%Last 12 months
Over the last 12 months, INVO Fertility’s net loss was 23.6% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About INVO Fertility Inc
NAYA Biosciences is a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune diseases, and women’s health. Our proven hub & spoke model harnesses the shared resources of a parent company and agility of lean strategic franchises, enabling efficient acquisition, development, and partnering of assets and allowing for optimized return on investment by combining scalable, profitable commercial revenues with the upside of innovative clinical-stage therapeutics. NAYA’s expanding portfolio of assets currently includes NY-303, a GPC3 x NKp46 bifunctional antibody for the treatment of hepatocellular carcinoma (HCC) with a unique mode of action targeting non-responders to the current immunotherapy standard of care (approximately 70% of the current treatable market) cleared to enroll patients in a Phase 1/2a monotherapy trial in 2025, NY-338, a CD38 x NKp46 bifunctional antibody for the treatment of multiple myeloma and autoimmune diseases with a differentiated safety and efficacy profile, NY-500, a PD-1 x VEGF bifunctional antibody for the treatment of HCC and other solid tumors, and NY-600 a PSMA x NKp46 bifunctional antibody for the treatment of metastatic Castration Resistant Prostate Cancer (mCRPC).
- Sector
- Healthcare
- Industry
- Medical Devices
- Headquarters
- Florida, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
IVF news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
IVF stock FAQ
What is IVF stock’s price today?
INVO Fertility (IVF) traded at $0.56 at the close on , down $0.03 (5.65%) from the previous close of $0.59. Over the past 52 weeks it has traded between $0.51 and $30.00.
If you invested $1,000 in IVF 10 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in IVF on would be worth about $0 at the close on , a total return of −100.0%. The same $1,000 would be worth $0 if invested five years ago and $10 if invested one year ago. Past performance doesn’t predict future returns.
What is INVO Fertility’s market cap?
INVO Fertility’s market capitalization is about $995.9 thousand. That’s Tiingo’s daily market cap for , at that day’s closing price of $0.56 (how market cap works).
How much revenue does INVO Fertility make?
INVO Fertility reported $7.5 million of revenue over the four quarters to , up 13.8% from the twelve months before. In its latest quarter (Q2 FY26, ended ) revenue was $2.2 million, up 16.7% from a year earlier.
Is INVO Fertility profitable?
Not over the four quarters to . INVO Fertility reported a net loss of $5.3 million across those four quarters on $7.5 million of revenue.
Does IVF pay a dividend?
INVO Fertility hasn’t paid a dividend in the last twelve months.
What is IVF’s 52-week high and low?
Over the past 52 weeks IVF has traded as low as $0.51 and as high as $30.00. At $0.56 at the close on , it is 98.1% below that high and 9.3% above the low.
What is IVF’s all-time high?
IVF’s highest closing price was $1,181,538.46 on , adjusted for stock splits. At $0.56 at the close on , it is 100.0% below that record.
Has IVF stock ever split?
Yes, seven times: 1-for-20 on ; 5-for-8 on ; 1-for-20 on ; 1-for-12 on ; 1-for-3 on ; 1-for-8 on ; 1-for-5 on .
How has IVF stock performed?
Including dividends and measured to the close on , IVF has returned −85.2% so far this year and −99.0% over the past year, and −100.0% over five years (−91.3% a year). Over the same periods the S&P 500, measured by SPY, returned +12.8%, +16.8% and +83.1%. Past performance doesn’t predict future returns.
What sector and industry is INVO Fertility in?
INVO Fertility is in the Healthcare sector and the Medical Devices industry, and is headquartered in Florida, USA.
What exchange does IVF trade on?
INVO Fertility trades on the Nasdaq under the ticker symbol IVF. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.